Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) EBIT (2023 - 2025)

Historic EBIT for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$33.8 million.

  • Inhibrx Biosciences' EBIT rose 2774.75% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.0 million, marking a year-over-year increase of 5834.88%. This contributed to the annual value of -$331.4 million for FY2024, which is 5119.35% down from last year.
  • Inhibrx Biosciences' EBIT amounted to -$33.8 million in Q3 2025, which was up 2774.75% from -$27.4 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' EBIT ranged from a high of -$27.4 million in Q2 2025 and a low of -$160.9 million during Q2 2024
  • For the 3-year period, Inhibrx Biosciences' EBIT averaged around -$61.1 million, with its median value being -$46.3 million (2023).
  • Per our database at Business Quant, Inhibrx Biosciences' EBIT tumbled by 28921.6% in 2024 and then surged by 8297.74% in 2025.
  • Quarter analysis of 3 years shows Inhibrx Biosciences' EBIT stood at -$88.3 million in 2023, then surged by 43.45% to -$49.9 million in 2024, then surged by 32.28% to -$33.8 million in 2025.
  • Its EBIT stands at -$33.8 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$42.9 million for Q1 2025.